Schaff Z, Lapis K
Semmelweis Orvostudományi Egyetem, Budapest.
Orv Hetil. 1990 Sep 2;131(35):1903-6.
The diagnosis of non-A, non-B (NANB) hepatitis was based on the exclusion of hepatitis A and B infection and other known causes of hepatitis, such as other viruses, alcohol and toxic effects. More recently, an RNA has been isolated from a NANB-infected chimpanzee serum and with its aid a polypeptide antigen was produced by molecular biological methods. Antibodies to this antigen--as part of the infectious agent, called hepatitis C virus (HCV)--were detected in the sera of infected patients. Studies with this antigen/antibody system proved, the HCV is responsible for the majority of posttransfusion and sporadic NANB hepatitis cases worldwide. The antibody appears late, in the serum up to 6 months after the infection. The occurrence of the infection is high among hemophiliacs and drug abusers. Anti-HCV antibody was detected also in certain liver disease with "unknown etiology" (chronic active hepatitis, primary biliary cirrhosis). This newly developed test provides the possibility to prove HCV infection in different groups of patients by detecting an antibody to a component of HCV.
非甲非乙型(NANB)肝炎的诊断是基于排除甲型和乙型肝炎感染以及其他已知的肝炎病因,如其他病毒、酒精和毒性作用。最近,从感染NANB的黑猩猩血清中分离出一种RNA,并借助分子生物学方法制备了一种多肽抗原。在受感染患者的血清中检测到针对这种抗原的抗体——作为感染因子的一部分,称为丙型肝炎病毒(HCV)。对这种抗原/抗体系统的研究证明,HCV是全球大多数输血后和散发性NANB肝炎病例的病因。抗体出现较晚,感染后血清中长达6个月才出现。血友病患者和药物滥用者中感染的发生率较高。在某些病因“不明”的肝病(慢性活动性肝炎、原发性胆汁性肝硬化)中也检测到了抗HCV抗体。这种新开发的检测方法通过检测针对HCV成分的抗体,为在不同患者群体中证明HCV感染提供了可能。